CTOs on the Move

Hospital Central Services

www.hcsc.org

 
Hospital Central Services is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.hcsc.org
  • 2171 28th St SW
    Allentown, PA USA 18103
  • Phone: 610.791.2222

Executives

Name Title Contact Details

Similar Companies

WellAWARE Systems

WellAWARE Systems, in partnership with Volunteers of America (VOA) and The Evangelical Lutheran Good Samaritan Society (GSS), offers the opportunity for enhanced quality of life for our aging population through an innovative approach to wellness and safety for senior living.

Inland Imaging Svc

Inland Imaging Svc is a Grand Terrace, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MMR Information Systems

MMRGlobal, Inc., formerly known as MMR Information Systems, Inc., provides secure, easy-to-use multilingual Personal Health Records (PHRs) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, professional organizations and affinity groups.

Lou Ruvo Brain Institute - Cleveland Clinic

Lou Ruvo Brain Institute - Cleveland Clinic is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Las Vegas, NV. To find more information about Lou Ruvo Brain Institute - Cleveland Clinic, please visit www.keepmemoryalive.org

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.